Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)
Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Iida M et al
What drug interactions are there with Bentyl
Glutathione S-Transferase M1 and T1 gene polymorphisms are not associated with increased risk of gestational diabetes mellitus development
Your personal timeline: what to expect week by week Here's where patients sometimes get discouraged, so it's worth being honest
The results suggest that, with proper supervision, a protein-rich diet, regular resistance training, and guidance from a trained medical provider, patients can decrease fat mass while minimizing muscle loss. We found that, under close supervision and regular follow-up from an obesity medicine specialist, patients were able to lose fat mass with only a minimal decline in muscle mass, Peralta-Reich added
.webp)
